The market expects Inspire Medical Systems (INSP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 10, 2025, might help the stock move higher if these ...

Financial Performance - Preliminary Q4 2024 revenues estimated between $239.5 million and $239.7 million, up 25% YoY, surpassing Zacks Consensus Estimate of $233 million [2] - Full-year 2024 revenues estimated between $802.6 million and $802.8 million, up 28% from 2023, exceeding Zacks Consensus Estimate of $796.1 million [5] - 2025 revenue guidance projected between $940 million and $955 million, reflecting 17-19% growth over 2024, with Zacks Consensus Estimate at $949.4 million [6] Business Expansion - Activated 72 new US medical centers in Q4 2024, bringing total to 1,435 centers implanting Inspire therapy [3] - Created 12 new US sales territories in Q4 2024, increasing total to 335 territories [3] - Implemented new organizational structure to fuel growth, including leadership team expansion [4] Product Development - Soft launched Inspire V neurostimulator in Q4 2024, with over 40 implants completed in Singapore and the US [7] - Introduced SleepSync programming system in Q3 2024, with full US availability expected in 2024 [12] Market Performance - Shares plunged 13.4% at yesterday's closing despite robust preliminary results [1] - Shares lost 11.4% between Oct 1 and Dec 31, 2024, compared to industry's 4.9% decline and S&P 500's 3.7% gain [10] Industry Comparison - Cencora (COR) gained 0.2% against industry's 12.7% decline between Oct 1 and Dec 31, 2024 [11] - Boston Scientific (BSX) rallied 6.2% against industry's 4.1% decline between Oct 1 and Dec 31, 2024 [14] - Cardinal Health (CAH) gained 7.2% compared to industry's 0.8% growth between Oct 1 and Dec 31, 2024 [16]

A Inspire. Inspire Medical Systems, Inc. JP Morgan Healthcare Conference January 13, 2025 NYSE: INSP © 2024 Inspire Medical Systems, Inc. All Rights Reserved INSPIRE CONFIDENTIAL. Inspire is a public company and has an Insider Trading Policy. The content in this deck is not to be shared with anybody outside of Inspire Medical Disclaimer From our entrepreneurial beginnings, and with a focus on delivering life-changing outcomes, we've been enhancing the lives of patients for over 17 years… >90,000 Patients tr ...

Financial Performance - Revenue for Q4 2024 is anticipated to be in the range of $239.5 million to $239.7 million, a 25% increase over Q4 2023 [6] - Revenue for full year 2024 is expected to be between $802.6 million and $802.8 million, a 28% increase over full year 2023 [6] - Initial full year 2025 revenue guidance is projected to be in the range of $940 million to $955 million, representing a 17% to 19% increase over full year 2024 [3] Business Highlights - Activated 72 new centers in the U.S. in Q4 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy [6] - Created 12 new sales territories in the U.S. in Q4 2024, increasing the total to 335 U.S. sales territories [6] - Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S. [6] Organizational Changes - Jason Kelly appointed as Chief Manufacturing and Quality Officer effective January 20, 2025, bringing 10 years of experience from Stryker Corporation [3] - Carlton Weatherby expanded role to Chief Strategy and Growth Officer, leading U.S. Sales, Marketing, and Strategy teams [4] - Randy Ban transitioned to EVP, Patient Access and Therapy Development, focusing on enhancing patient outcomes and access to Inspire therapy [5] - Ivan Lubogo moved to SVP, Strategic Sales, leading a new team focused on Integrated Delivery Networks and strategic accounts [7] - Joe Sander promoted to SVP U.S. Sales, leveraging over 20 years of sales management experience [8] Leadership and Strategy - The company implemented a new organizational structure to drive continued growth and advance the adoption of Inspire therapy [6] - The leadership changes are aimed at fueling growth, enhancing patient outcomes, and expanding market reach [3][4][5][7][8] Market and Product Development - Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for moderate to severe obstructive sleep apnea [11] - The company is focused on expanding its leadership team and enhancing its commercial strategy to capitalize on growth opportunities [3][4]

VANCOUVER, British Columbia and AUSTIN, Texas, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for High Performance Computing (HPC), AI, graph analytics, and other compute-intensive workloads, announces that it has issued an aggregate of 5,031.25 proportionate voting shares in the capital of the Company (the "PV Shares") at a deemed issu ...

Core Viewpoint - Inspire Medical Systems, Inc. is set to release its financial results for the fourth quarter and fiscal year 2024 on February 10, 2025, followed by a conference call to discuss these results and recent business developments [1]. Financial Results Announcement - The financial results will be announced after the close of trading on February 10, 2025 [1]. - A conference call will take place at 5:00 p.m. Eastern Time to discuss the results [1]. Conference Call Details - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For those wishing to ask questions, registration is required, and an email will be sent with dial-in details and a unique access code [3]. - It is recommended to register at least 10 minutes before the call starts to ensure connection [3]. Replay Information - A replay of the conference call will be available on the Company's Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].

Core Insights - Inspire Medical Systems, Inc. is a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 11:15 a.m. Eastern Time [2] Company Overview - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company focuses on the development and commercialization of innovative solutions for patients suffering from this condition [3] Investor Relations - The presentation will be accessible via a live webcast, and replays will be available for two weeks following the event [4]

VANCOUVER, British Columbia and AUSTIN, Texas, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that provides revolutionary high-performance, energy-efficient accelerated computing solutions for High Performance Computing (HPC), AI, graph analytics, and other compute-intensive workloads, announces that following the approval of a majority of the minority of the Company’s shareholders at an annual general and special me ...

Group 1 - BofA Securities has upgraded Inspire Medical Systems from Neutral to Buy, indicating the company is now categorized under profitable growth [1][3][6] - Inspire Medical is expected to provide its 2025 revenue guidance in early January, aligning with its fourth-quarter results, and is comfortable with the consensus of $950 million in revenue for 2025 [1][3] - For 2024, Inspire Medical anticipates sales between $793 million and $798 million, slightly above prior guidance and in line with consensus estimates [2] Group 2 - The company's growth outlook for 2025 includes plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and enhance capacity [3] - The Inspire V system, approved by the FDA, is expected to simplify procedures and increase accessibility for various types of surgeons, with a soft launch planned for late 2024 and a full launch in 2025 [4][5] - The analyst notes that Inspire Medical is positioned as an attractive smid cap growth stock with potential for double-digit margins, which could lead to increased strategic interest [6]

MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Inspire is scheduled to present at 7:30 a.m. Eastern Time. The presentation will be accessible via a live webcast ...